Lv4
470 积分 2025-03-15 加入
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
1个月前
已完结
Density of T cell subsets in colorectal cancer in relation to disease-specific survival
2个月前
已完结
B Cell Development and Maturation
2个月前
已完结
Early immune evasion in colorectal cancer: interplay between stem cells and the tumor microenvironment
2个月前
已完结
MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis
2个月前
已完结
Comparison of Immune Microenvironment Between Colon and Liver Metastatic Tissue in Colon Cancer Patients with Liver Metastasis
2个月前
已完结
Investigating the Impact of B Cell‐Related Genes on Colorectal Cancer Immunosuppressive Environment and Immunotherapy Evasion
2个月前
已完结
Regulatory B cells in inflammatory diseases and tumor
2个月前
已完结
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
2个月前
已完结
Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment
2个月前
已完结
皖公网安备34019202002308
